Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
LGC Biosearch Technologies is a premier global provider of genomic analysis tools and specialty reagents, widely recognized for its invention of the Black Hole Quencher (BHQ) and BlackBerry Quencher (BBQ) technologies. The company specializes in the design and large-scale manufacture of custom oligonucleotides, fluorophores, and phosphoramidites, the latter of which are often marketed under the Biosearch Organics brand. Its products are industry standards for real-time PCR, molecular diagnostics, and next-generation sequencing (NGS) applications. Following its acquisition by LGC Group in 2015, the company serves as the core of LGC's genomics division, supporting customers across the clinical, agricultural, and pharmaceutical research sectors. Biosearch maintains ISO 9001 and ISO 13485 certified facilities to ensure high-quality production for regulated diagnostic markets.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Biosearch Organics.